AnaptysBio Inc. (NASDAQ: ANAB) appointed Christopher Murphy as chief financial officer and Owen Hughes to its board of directors, according to a company statement.

Murphy previously served as CFO and chief business officer at Third Harmonic Bio and held senior leadership positions at Horizon Therapeutics, which Amgen acquired for $28 billion in 2023. He has experience in business development, corporate strategy and investment banking, including work at JMP Securities.

Hughes brings more than 20 years of experience in royalty management and corporate development. He currently serves as CEO of XOMA Royalty and previously led Sail Bio and Cullinan Oncology. Hughes spent 16 years in investment roles at Brookside Capital and Pyramis Global Advisors and currently sits on the board of C4 Therapeutics.

"We are excited to welcome Chris, who will be fully dedicated to Anaptys, and Owen, both of whom deepen our team's strong mix of expertise across finance, business development, royalty management and strategic transactions," said Daniel Faga, president and CEO.

Anaptys manages financial collaborations for Jemperli with GSK and imsidolimab with Vanda Pharmaceuticals. The company focuses on managing royalty assets from these drug partnerships.